Role of Zinc and HAP in Inducing Sub-Retinal Pigmented Epithelium Deposits and Age-Related Macular Degeneration
About the Research Project
Program
Award Type
Standard
Award Amount
$120,000
Active Dates
July 01, 2014 - June 30, 2016
Grant ID
M2014085
Acknowledgement
Co-Principal Investigator(s)
Imre Lengyel, PhD, University College London (UK)
Goals
We have discovered what appears to be an early step in the process of developing deposits known as drusen in the aging retina, which can lead to age-related macular degeneration (AMD). We believe that zinc and inflammation are involved, and have developed a method for visualizing when the step has occurred in the intact eye.
Summary
The thrust of our project is to see how zinc and inflammation are involved in this step, and how early and broadly the step may occur in ordinary eyes: does the step happen at 40 years of age, or at 60 years of age, and does it occur in everybody? We anticipate our visualization method may be usable as a screening test for AMD (patent pending), and that our improved understanding of how AMD develops may lead to new, early treatments.
Related Grants
Macular Degeneration Research
New Drug Delivery Approach to Transform Macular Degeneration Treatment
Active Dates
July 01, 2025 - June 30, 2028
Principal Investigator
Daisy Shu, PhD
Current Organization
University of New South Wales
New Drug Delivery Approach to Transform Macular Degeneration Treatment
Active Dates
July 01, 2025 - June 30, 2028
Principal Investigator
Daisy Shu, PhD
Current Organization
University of New South Wales
Macular Degeneration Research
A Novel Implantable Device to Treat Wet Macular Degeneration
Active Dates
July 01, 2025 - June 30, 2028
Principal Investigator
Charles DeBoer, MD, PhD
Current Organization
Stanford University
A Novel Implantable Device to Treat Wet Macular Degeneration
Active Dates
July 01, 2025 - June 30, 2028
Principal Investigator
Charles DeBoer, MD, PhD
Current Organization
Stanford University
Macular Degeneration Research
The Development of a Transplant-Independent Therapy for RPE Dysfunction
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Shintaro Shirahama, MD, PhD
Current Organization
Schepens Eye Research Institute of Massachusetts Eye and Ear
The Development of a Transplant-Independent Therapy for RPE Dysfunction
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Shintaro Shirahama, MD, PhD
Current Organization
Schepens Eye Research Institute of Massachusetts Eye and Ear